Building a Target Product Profile (TPP) starts with the right questions. Work through the core dimensions of your program — indication scope, competitive differentiation, regulatory context — and when the answers take shape, let the agent turn them into an initial framework.
Each one shows the prompt we'd actually run, a snippet of what Cheiron returns, and a link to the full grounded response with citations.
New to Cheiron? Start with Getting Started with Cheiron and How Cheiron Grounds Answers (Deep Citations) — they explain why every answer below is auditable back to it's source.
Define Indication Scope and Target Patient Population
Clarify Who your Program Is For — and Why
Example question:
"For a tissue-agnostic oncology program in advanced solid tumors, what patient population characteristics, including biomarker status, prior treatment history, and tumor type, are most commonly used to define an initial development population?”
Cheiron’s response:
For an initial tissue-agnostic advanced solid-tumor program, the most common starting population is patients with unresectable, locally advanced, metastatic, recurrent, or otherwise incurable solid tumors that harbor a defined actionable biomarker, have measurable disease, good performance status, and have progressed after standard therapy or...
Tip: Examine the disease landscape and patient journey to define which population your program is best positioned to serve, and what clinical rationale supports that choice.
Benchmark Competitive Differentiation
Identify Where Your Asset Can Credibly Differentiate
Example question:
"What clinical and product attributes are most commonly used to differentiate tissue-agnostic oncology therapies across approved and late-stage programs?”
Cheiron’s response:
The most common differentiators for tissue-agnostic oncology therapies are biomarker definition/testability, breadth of tumor coverage, response magnitude and durability, consistency across histologies, evidence maturity, line-of-therapy restrictions, route/formulation, safety liabilities, pediatric/CNS/rare-tumor applicability, and...
Tip: Map approved and late-stage competing therapies to understand what's already been established — and where meaningful differentiation remains possible.
Assess Regulatory Context
Understand What Regulators Will Expect at Your Development Stage
Example question:
"What regulatory considerations are most important when designing an early-stage tissue-agnostic oncology development program, including patient selection strategy, endpoint expectations, and master protocol considerations?”
Cheiron’s response:
A tissue-agnostic oncology program should not be treated as the default path simply because a drug has a molecular target. FDA’s core concern is whether efficacy and safety can be scientifically generalized across tumor types that share the alteration, especially when some tumor types may have few or no enrolled patients. The early program should...
Tip: Review regulatory guidance relevant to your indication and geography to clarify the evidence standards, endpoint expections, and pathway assumptions your TPP should be built around.
Agent — Generate an Initial ‘Target Product Profile (TPP)’ Framework
Turn Your Inputs Into a Starting Framework
Provide your program's key parameters, and Cheiron's Workflow Agent will generate an initial TPP framework across indication, efficacy and safety direction, dosing considerations, regulatory pathway, and competitive positioning — a starting point to build.
Learn More: Workflow Agent Guide
These examples are only a starting point. To explore additional questions, see Ask Cheiron for guidance on writing questions and reviewing answers.